全球心臟瓣膜刀市场 - 2023-2030

概述

心臟瓣膜切开器是一种手术器械，用于在瓣膜成形术和瓣膜置换手术等医疗手术中切割或切开心臟瓣膜。

瓣膜切开术是一种使用瓣膜切开器来缓解瓣膜狭窄或逆流的外科手术。这是透过在受影响的瓣膜小叶中创建受控切口来完成的。这些切口可以扩大狭窄的瓣膜并改善其功能，这有助于恢復心臟内的正常血流。心臟外科医师使用瓣膜刀来治疗瓣膜相关疾病并改善心臟功能和患者福祉。

市场动态：驱动因素与限制因素

主动脉瓣狭窄盛行率的增加预计将推动市场成长

使用心臟瓣膜切开器有助于治疗主动脉瓣狭窄，这是一种导致主动脉瓣狭窄并阻碍血液从心臟左心室流向身体其他部位的疾病。当严重的主动脉瓣狭窄病例需要手术介入时，可以使用瓣膜切开术进行瓣膜切开术。

在这种医疗手术中，对主动脉瓣的厚瓣或融合瓣叶进行精确切割，以扩大其开口。这可以提高瓣膜的灵活性并减轻心臟的压力，从而短期缓解胸痛和呼吸困难等症状。然而，这可能不是一个永久的解决方案。

此外，欧洲心臟学会指出，主动脉瓣狭窄（AS）在65岁以下无先天性异常的人群中并不常见，但其盛行率随着年龄的增长而增加。在美国，它是第二常见的瓣膜病变。 65岁时，约有5%的人口患有AS，且其盛行率随着年龄的增长而显着增加。

此外，根据最近的研究，大约 12.4% 的人口患有 AS，其中 3.4% 在 75 岁及以上的人口中出现严重症状。 AS的盛行率随着年龄的增长而显着增加，从50-59岁年龄组的0.2%到80-89岁年龄组的9.8%不等。每年大约有千分之五的人会出现新的 AS 病例，这种情况通常发生在 60 岁左右的人群中。

对于患有临床显着的AS 的年轻人来说，二尖瓣主动脉瓣疾病很常见，而三尖瓣主动脉瓣狭窄在70 岁以上的老年人中更为普遍，通常需要主动脉瓣置换术。二叶式主动脉瓣并不罕见，大约有 0.5-0.8% 的人口患有这种情况。在高收入国家，AS 的负担日益增加，预计到 2050 年，需要治疗的老年患者（75 岁及以上有严重症状的 AS）将显着增加，在美国和欧洲将翻倍。预计到 2040 年，冰岛 70 岁以上人口中严重 AS 的盛行率将增加一倍，到 2060 年将增加两倍。

此外，包括瓣膜修復在内的心臟手术数量不断增加，以及人们对心臟瓣膜疾病早期诊断和治疗重要性的认识不断提高，预计将在预测期内推动市场发展。

克制：

心臟瓣膜手术和相关手术费用昂贵，有出血、感染和附近结构损坏的潜在风险，而替代方案的可用性是预计在预测期内阻碍市场的因素。

目录

第 1 章：方法与范围

• 研究方法论
• 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

• 按产品类型分類的片段
• 按手术类型分類的片段
• 最终使用者的片段
• 按地区分類的片段

第 4 章：动力学

• 影响因素
  • 司机
    • 主动脉瓣狭窄盛行率增加
  • 限制
    • 与瓣膜刀相关的风险
  • 机会
  • 影响分析

第 5 章：产业分析

• 波特五力分析
• 供应链分析
• 定价分析
• 监管分析
• 管道分析
• 专利分析
• DMI 意见

第 6 章：COVID-19 分析

• COVID-19 分析
  • 新冠疫情爆发前的情景
  • 新冠疫情期间的情景
  • 新冠疫情后的情景
• COVID-19 期间的定价动态
• 供需谱
• 疫情期间政府与市场相关的倡议
• 製造商策略倡议
• 结论

第 7 章：按产品类型

• 可扩张心臟瓣膜刀
• 有线心臟瓣膜切开器

第 8 章：依手术类型

• 瓣膜切开术
• 二尖瓣连合切开术
• 主动脉瓣连合切开术
• 三尖瓣连合切开术
• 其他的

第 9 章：最终用户

• 医院
• 门诊手术中心
• 心臟手术中心
• 心导管实验室
• 其他的

第 10 章：按地区

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地区
• 亚太
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 亚太其他地区
• 中东和非洲

第 11 章：竞争格局

• 竞争场景
• 市场定位/份额分析
• 併购分析

第 12 章：公司简介

• LeMaitre Vascular
• 公司简介
• 产品组合和描述
• 财务概览
• 主要进展
• B. Braun SE
• Andramed GmbH
• LimFlow, Inc.
• Teleflex Incorporated
• Symmetry Surgical Inc.

第 13 章：附录

Overview

A cardiac valvulotome is a surgical instrument used to cut or incise heart valves during medical procedures such as valvuloplasty and valve replacement surgeries.

Valvulotomy is a surgical procedure that uses a valvulotome to alleviate valve stenosis or regurgitation. This is done by creating controlled incisions in the affected valve leaflets. These incisions can widen narrowed valves and improve their functionality, which helps to restore proper blood flow within the heart. Cardiac surgeons use valvulotomes to treat valve-related diseases and improve cardiac function and patient well-being.

Market Dynamics: Drivers and Restraints

Increasing prevalence of aortic stenosis is expected to drive market growth

The use of a cardiac valvulotome can be beneficial in treating aortic stenosis, which is a condition that causes the aortic valve to narrow and impede the flow of blood from the heart's left ventricle to the rest of the body. When surgical intervention is necessary for severe cases of aortic stenosis, a valvulotomy procedure can be conducted using a valvulotome.

In this medical procedure, precise cuts are made in the thick or fused leaflets of the aortic valve to widen its opening. This improves the flexibility of the valve and reduces pressure on the heart, providing short-term relief from symptoms like chest pain and breathlessness. However, it may not be a permanent solution.

Moreover, the European Society of Cardiology states that Aortic stenosis (AS) is not very common in people under 65 years of age without a congenital abnormality, but its prevalence increases with age. In the United States, it is the second most common valvular lesion. At the age of 65, about 5% of the population has AS and its prevalence increases significantly with age.

In addition, according to recent studies, approximately 12.4% of the population has AS, with 3.4% experiencing severe symptoms among those aged 75 and older. The prevalence of AS increases significantly with age, ranging from 0.2% in the 50-59 age group to 9.8% in those aged 80-89 years. Around 5 in 1,000 individuals experience new cases of AS each year, and this typically occurs in people around the age of 60.

It is common for younger people with clinically significant AS to have bicuspid aortic valve disease, while tricuspid aortic valve stenosis becomes more prevalent in those over 70 years old, often requiring aortic valve replacement. Bicuspid aortic valves are not uncommon, occurring in approximately 0.5-0.8% of the population. In high-income countries, there is an increasing burden of AS, with a significant rise in elderly patients needing treatment (severe symptomatic AS aged 75 years and above) projected by 2050, doubling in both the USA and Europe. Iceland is also expected to have a doubling in the prevalence of severe AS among those aged ≥70 by 2040, with a tripling expected by 2060.

Furthermore, the rising number of cardiac surgeries, including valve repair, and increasing awareness of the importance of early diagnosis and treatment of heart valve conditions are the factors the market is expected to drive the market over the forecast period.

Restraint:

Cardiac valve surgeries and associated procedures are expensive, with potential risks of bleeding, infection, and damage to nearby structures, and the availability of alternatives are the factors expected to hamper the market over the forecast period.

Segment Analysis

The global cardiac valvulotome market is segmented based on product type, surgery type, end user, and region.

The Expandable Cardiac Valvulotome from the Product Type Segment Accounted for Approximately 37.6% of the Cardiac Valvulotome Market Share

Expandable cardiac valvulotomes are becoming more common in modern surgical practice. These devices offer flexibility and adjustability to surgeons and enable the controlled expansion or dilation of valve leaflets. They are precise and versatile, making them suitable for various valve-related procedures like valvuloplasty and valvulotomy. The expandable cardiac valvulotomes are particularly useful in treating valve stenosis and regurgitation.

Moreover, the increasing prevalence of valve diseases, the growing aging population, and advancements in cardiac surgery are the factors expected to drive the market over the forecast period.

For instance, advancements in cardiac surgery have led to the development of more sophisticated and precise instruments, such as Expandable Cardiac Valvulotomes. These tools play a crucial role in transcatheter aortic valve replacement (TAVR) procedures.

TAVR is a less intrusive method of treating aortic valve stenosis, which previously required open-heart surgery. This procedure involves using a catheter to deliver a collapsible artificial valve to the heart, typically through a small incision in the groin or chest.

Before the deployment of a new artificial valve, expandable cardiac valvulotomes are used to either predilate or enlarge the native aortic valve, guaranteeing a secure fit and optimal functionality. The use of instruments like expandable cardiac valvulotomes in TAVR, a minimally invasive procedure, minimizes patient trauma, shortens hospital stays, and speeds up recovery compared to traditional open-heart surgery. This innovation highlights how precise instruments are crucial in modern cardiac surgery, improving patient outcomes, and transforming treatment approaches for valvular heart diseases. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America accounted for approximately 40.3% of the market share in 2022

North America is expected to hold the largest market share owing to the presence of key players, and the increasing prevalence of valvular heart disease.

For instance, according to data from the Centers for Disease Control and Prevention (CDC), Americans suffer from valvular heart disease, and this number tends to increase among older adults. Among the population, approximately 1 in 40 people experience significant valvular heart disease. The mitral and aortic valves are most commonly affected, with around 4 million Americans experiencing significant mitral valve regurgitation. Additionally, roughly 250,000 new cases are diagnosed each year.

The statistics show that many patients require treatment for valvular heart diseases, with the mitral and aortic valves being particularly affected. This widespread occurrence of heart conditions is likely to increase the need for cardiac valvulotomes and other surgical interventions, leading to growth in the cardiac valvulotome market as healthcare providers work to find effective solutions for this common health problem. Hence, owing to the above factors, the North America region is expected to hold the largest market share over the forecast period.

COVID-19 Impact Analysis:

The COVID-19 pandemic significantly impacted the cardiac valvulotome market by leading to a reduction in the number of cardiac surgeries and valvulotomy procedures performed. For instance, a study was conducted in Lithuania to assess how the COVID-19 pandemic affected a cardiac surgery center's operations. The study revealed that the pandemic had a considerable impact on adult cardiac surgery, resulting in a decline in surgical procedures and a rise in mortality rates. Despite the increased risk of complications in COVID-19-positive patients, the study found that carrying out planned cardiac surgeries with appropriate protective measures during quarantine was a better alternative than completely halting elective cardiac surgeries.

Furthermore, the primary causes of this decrease were the reallocation of healthcare resources to address the surge in COVID-19 cases, the prioritization of critical care, and many patients' reluctance to seek medical attention for non-emergency conditions due to infection concerns. As a result, demand for valvulotomy procedures dropped temporarily, affecting the market. However, as healthcare systems gradually adjusted and resumed elective procedures, the market began to recover, highlighting the resilience of cardiac valvulotome procedures as necessary treatments for valvular heart diseases.

Competitive Landscape

The major global players in the cardiac valvulotome market include: LeMaitre Vascular, B. Braun SE, Andramed GmbH, LimFlow, Inc., Teleflex Incorporated, and Symmetry Surgical Inc. among others.

Why Purchase the Report?

• To visualize the global cardiac valvulotome market segmentation based on product type, surgery type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cardiac valvulotome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global cardiac valvulotome market report would provide approximately 49 tables, 57 figures, and 170 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Surgery Type
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of aortic stenosis
  • 4.1.2. Restraints
    • 4.1.2.1. Risk associated with valvulotome
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Pipeline Analysis
• 5.6. Patent Analysis
• 5.7. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Expandable Cardiac Valvulotome*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Over the Wire Cardiac Valvulotome

8. By Surgery Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 8.1.2. Market Attractiveness Index, By Surgery Type
• 8.2. Valvulotomy*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Mitral Valve Commissurotomy
• 8.4. Aortic Valve Commissurotomy
• 8.5. Tricuspid Valve Commissurotomy
• 8.6. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Ambulatory Surgical Center
• 9.4. Cardiac Surgery Centers
• 9.5. Cardiac Catheterization Labs
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. LeMaitre Vascular*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. B. Braun SE
• 12.3. Andramed GmbH
• 12.4. LimFlow, Inc.
• 12.5. Teleflex Incorporated
• 12.6. Symmetry Surgical Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us